A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors

Stopped early · Phase 2

Conditions studied: Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit

In brief

In this study, patients with advanced solid tumors will undergo \[18F\]F AraG PET/CT imaging to assess for changes in tracer uptake following treatment with CkIT.

Key facts

Study ID

NCT04260256

Run by

CellSight Technologies, Inc.

People needed

9

Starts

2022-03-01

Expected to finish

2026-03-01

Last updated by the study team

2026-03-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Solid tumor with planned CkIT
• Must be >18 years old
• Signed Informed Consent Form
• Patient must have two qualifying lesions

You may not qualify if…

• Patient is pregnant or breast feeding

Where it is running

• Stanford University — Stanford, California, United States
• Oregon Health and Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.